secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apimeds Pharmaceuticals US, Inc. (APUS)
CIK:        0001894525
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001213900-26-034786
Event type: litigation
Sentiment:  negative
Materiality: 0.85
Item codes: 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apimeds faces hostile takeover attempt by Inscobee; company says consent void, files emergency action
--------------------------------------------------------------------------------

- On March 20, 2026, Inscobee and Apimeds Korea claimed to remove all four directors and CEO/CFO via written consent.
- Company states the consent violates the irrevocable proxy granted under the Support Agreement from Dec 1, 2025.
- Inscobee used 6,416,365 shares subject to proxy; without those, consent lacks majority under Delaware law.
- Company will file emergency action in Delaware Court of Chancery under 8 Del. C. § 225 to void consent.
- Purported new board approved business expansions without authorization; company disputes them.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026034786/0001213900-26-034786-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026034786/ea0283550-8k_apimeds.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-034786

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer